New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:06 EDTENDP, BDSIEndo, BioDelivery Sciences announces positive results from buprenorphine trial
Endo Pharmaceuticals, a subsidiary of Endo International (ENDP) and BioDelivery Sciences (BDSI) announced positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. The trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to placebo. Additional secondary endpoints were supportive of the efficacy of BEMA buprenorphine compared to placebo. The most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea and vomiting.
News For ENDP;BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
16:35 EDTENDPEndo sees Auxilium transaction immediately accretive
Endo International plc (ENDP)announced it has completed the acquisition of Auxilium Pharmaceuticals (AUXL) in a transaction valued at $2.6B when announced on October 9, 2014. The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27 and the receipt of all required regulatory approvals. Rajiv De Silva, president and CEO of Endo, stated, This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality products to our already robust portfolio and expanding our development pipeline. We are excited to deliver on the promise of this combination by leveraging our resources to enhance the performance of XIAFLEX and optimize TESTOPEL and STENDRA. We continue to expect the transaction to be immediately accretive for shareholders and meaningfully accretive each year moving forward. We believe that Endo is now even better positioned to drive growth across our product portfolio and to capitalize on additional future strategic M&A opportunities to create value for shareholders, customers and employees." Auxilium common stock will cease to be traded on the NASDAQ Global Market following the close of trading on January 29.
January 27, 2015
09:35 EDTENDPAuxilium shareholders approve merger with Endo
Subscribe for More Information
08:18 EDTBDSIBioDelivery Sciences launch of Bunavail in upward trend, says Summer Street
Subscribe for More Information
07:09 EDTBDSIBioDelivery Sciences enters into agreement with MEDA for ONSOLIS
Subscribe for More Information
January 22, 2015
14:03 EDTENDPAuxilium to host special shareholder meeting
Subscribe for More Information
January 21, 2015
18:27 EDTENDPOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
18:06 EDTENDPS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
17:19 EDTENDPBoston Beer to replace Endo in S&P 400 as of 1/26 close
Subscribe for More Information
17:18 EDTENDPEndo to replace Covidien in S&P 500 as of 1/26 close
January 20, 2015
07:00 EDTENDPEndo price target raised to $98 from $86 at Piper Jaffray
Piper Jaffray raised its price target for Endo shares to $98 saying Xiaflex's market expansion opportunities are not fully appreciated by the broader market. It keeps an Overweight rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use